ACPE UAN #: 0233-0000-17-001-H04-P
Release Date: May 27, 2017
Expiration Date: May 27, 2020
Activity Type: Knowledge-based
Credit Hours: 1.5 contact hours
Activity Fee: Member: $15.00 Non-Member: $30.00
Advances in cancer genomics have paved the way for a new era of precision medicine in oncology—an era in which a patient’s tumor can be characterized extensively for mutations and other molecular abnormalities, and treatment can be based mainly on the identified molecular changes (not just the type of cancer). Although these advances are both promising and exciting, clinicians and payers alike are struggling to translate the results of genetic tumor analysis into optimal patient care that provides both superior outcomes and satisfactory value. This session provides an in-depth look at the reality and promise of precision medicine in oncology. You will learn the steps involved in going from identifying patients who are candidates for tumor sequencing to making clinical recommendations based on test results. Along the way, you will become acquainted with the assays used most commonly to characterize tumors and the evidence employed to guide patient-specific treatment options. A concluding panel discussion will address the many challenges posed to payers by a treatment approach still very much in its infancy.
Target audience: This program was designed for managed care pharmacists and those with an interest in the management of specialty pharmacy utilization and spend.
At the completion of this activity, participants should be able to:
- Define terms used commonly in cancer genomics and precision medicine.
- Identify the people and tasks associated with selecting patients for tumor genetic testing and interpreting test results.
- Explain how an interprofessional molecular tumor board uses information about a patient’s tumor mutations to inform an evidence-based treatment plan.
- Recognize possible solutions to challenges payers face in melding precision medicine with population management.
Method and CE Requirements:
Participants should claim continuing pharmacy education (CPE) credit for this Specialty Pharmacy Connect home study activity, only if they have not claimed credit for the live activity presented in conjunction with AMCP Annual Meeting 2017. CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP CPE Monitor account .
Pharmacists interested in obtaining CPE credit must:
- Review the full content of the activity.
- Complete a Post-Test which requires a passing score of 70% or higher. It may be taken a maximum of three times.
- Complete a specific evaluation.
System Technical and Internet Requirements:
System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites. View the minimum technical and system requirements for continuing education online learning activities. Contact US.
Faculty Relevant Financial Relationships Disclosure:
AMCP asks everyone who is in a position to control the content of a continuing pharmacy education activity to disclose all relevant financial relationships with commercial interests. If AMCP determines that a conflict of interest exists as a result of a financial relationship you have (or that your spouse/partner has), we will need to take appropriate steps to resolve the conflict of interest.
|The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE).|
As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.
L.Belin, et al. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. Ann Oncol 2017; 28 (3) : 590-596. doi: 10.1093/annonc/mdw666. Reproduced with persmission of Oxford University Press on behalf of the European Socienty for Medical Oncology.
Statement of Commercial Support
This activity is supported by an independent educational grant from Merck & Co., Inc.
Meet the Moderator- Susan C. Winckler's biography.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE UAN #0233-0000-17-001-H04-P||1.5 Contact Hours||March 27, 2017 - March 27, 2020|